Highly sensitive detection of CpG methylation in genomic DNA by AuNP-based colorimetric assay with ligase chain reaction

2015 ◽  
Vol 51 (16) ◽  
pp. 3371-3374 ◽  
Author(s):  
Fengxia Su ◽  
Limei Wang ◽  
Yueying Sun ◽  
Chenghui Liu ◽  
Xinrui Duan ◽  
...  

Using LCR amplification and AuNP-based colorimetric detection, a highly sensitive and selective method for detection of DNA methylation has been developed.

2020 ◽  
Vol 12 (26) ◽  
pp. 3361-3367
Author(s):  
Wenshuai Li ◽  
Guorui Wu ◽  
Min Wang ◽  
Aiqin Yue ◽  
Weijun Du ◽  
...  

We propose a colorimetric assay based on the coupling of gap ligase chain reaction (Gap-LCR) with DNAzyme to detect the target GmSg-1 genes of class A soybean saponins with the naked eye, without the involvement of expensive instruments.


2015 ◽  
Vol 51 (54) ◽  
pp. 10953-10956 ◽  
Author(s):  
Yuling Wang ◽  
Eugene J. H. Wee ◽  
Matt Trau

Highly sensitive DNA methylation analysis at CpG resolution is demonstrated by employing SERS nanotags via ligase chain reaction (LCR) and validated with sequencing.


Nanoscale ◽  
2014 ◽  
Vol 6 (6) ◽  
pp. 3055-3058 ◽  
Author(s):  
Xinjian Yang ◽  
Zhiqiang Gao

By combining terminal protection of small molecule (folate)-capped DNA probes, exonuclease III signal amplification and gold nanoparticles, we developed a simple and label-free colorimetric assay for highly sensitive detection of folate receptor.


2015 ◽  
Vol 6 (3) ◽  
pp. 1866-1872 ◽  
Author(s):  
Fengxia Su ◽  
Limei Wang ◽  
Yueying Sun ◽  
Chenghui Liu ◽  
Xinrui Duan ◽  
...  

Multiple CpG methylation can be accurately detected in one-tube ligase chain reaction (LCR) amplification with high sensitivity and specificity.


RSC Advances ◽  
2015 ◽  
Vol 5 (55) ◽  
pp. 44714-44721 ◽  
Author(s):  
Siqi Zhang ◽  
Kun Wang ◽  
Zhenyu Li ◽  
Zhongmin Feng ◽  
Ting Sun

Upon adding THBV, the self-assembly of THBV with H1 allows the rest of the DNA sequence of H1 to accelerate H1–H2 complex formation. The G-quadruplex at the end of the H1–H2 complex could catalyze TMB into a colored product.


Nanoscale ◽  
2018 ◽  
Vol 10 (12) ◽  
pp. 5466-5473 ◽  
Author(s):  
Attasith Parnsubsakul ◽  
Sukunya Oaew ◽  
Werasak Surareungchai

Recyclable zwitterionic peptide-capped AuNPs for highly sensitive detection of Ni2+.


Talanta ◽  
2010 ◽  
Vol 80 (5) ◽  
pp. 1725-1729 ◽  
Author(s):  
Xiangxian Meng ◽  
Xiaohai Yang ◽  
Kemin Wang ◽  
Qiuping Guo ◽  
Yongjun Tan ◽  
...  

2005 ◽  
Vol 23 (17) ◽  
pp. 3897-3905 ◽  
Author(s):  
Wolfram E. Samlowski ◽  
Sancy A. Leachman ◽  
Mark Wade ◽  
Pamela Cassidy ◽  
Patricia Porter-Gill ◽  
...  

Purpose The nucleoside analog 5-aza-2′-deoxycytidine (5-aza-CdR, decitabine) is a potent inhibitor of DNA methylation in vitro. Cellular treatment with this agent induces the re-expression of methylation-silenced genes. It remains unclear to what extent this compound inhibits DNA methylation in vivo. A clinical study was designed to examine the molecular effects and toxicity of a continuous 1-week intravenous infusion of decitabine in solid tumor patients. Methods Ten patients with refractory solid tumors were included in this study. Decitabine was administered at 2 mg/m2/d via continuous infusion for 168 hours. Quantitative polymerase chain reaction and high performance liquid chromatography were utilized to measure promoter-specific and global DNA methylation in peripheral-blood cells before and after treatment. Results Transient grade III/IV neutropenia (two patients) and grade II thrombocytopenia (one patient) was observed at the lowest planned dose step (2 mg/m2/d for 7 days). Nonhematologic toxicities were not observed. Quantitative polymerase chain reaction demonstrated significant MAGE-1 promoter hypomethylation by 14 days after the start of treatment in all 13 treatment cycles examined. Significant genomic DNA hypomethylation was also seen by day 14 in 11 of 13 treatment cycles analyzed. Genomic DNA methylation reverted to baseline levels by 28 to 35 days after the start of treatment, demonstrating that inhibition of DNA methylation by decitabine is transient. Conclusion A 168-hour continuous infusion of decitabine is well tolerated and results in the inhibition of promoter-specific and genomic DNA methylation in vivo. This treatment schedule is suitable for evaluation of decitabine in combination with agents whose activity may be enhanced by the reversal of DNA methylation–mediated gene silencing.


2016 ◽  
Vol 6 (1) ◽  
Author(s):  
Peiyan Xie ◽  
Longjiao Zhu ◽  
Xiangli Shao ◽  
Kunlun Huang ◽  
Jingjing Tian ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document